Press Coverage

FDA Clearance for Cellvizio + Pafolacianine for Molecular Imaging

9 May 2022

The US FDA has granted 510(k) clearance (K220477) for the use of the Cellvizio 100 Series platform with a molecular imaging agent called Pafolacianine (Cytalux) for real-time in vivo visualization during endoscopic, laparoscopic, and needle-based procedures, according to Mauna Kea Technologies.

Latest News

Mauna Kea Technologies Announces the Results of its Combined General Meeting of June 4, 2026

Mauna Kea Technologies Announces the Results of its Combined General Meeting of June 4, 2026

Mauna Kea Technologies Announces New Publication in the UEG Journal Identifying “Triple Healing”, a Cellvizio®— Assessed Therapeutic Target Associated with Sustained Remission in Ulcerative Colitis

Mauna Kea Technologies Announces New Publication in the UEG Journal Identifying “Triple Healing”, a Cellvizio®— Assessed Therapeutic Target Associated with Sustained Remission in Ulcerative Colitis

Mauna Kea Technologies Expands Presence in the Middle East with UAE and Turkey Regulatory Approvals and First CellTolerance® Commercial Installation

Mauna Kea Technologies Expands Presence in the Middle East with UAE and Turkey Regulatory Approvals and First CellTolerance® Commercial Installation

No results found.